S. Baruchel

C. Hawkins, S. Baruchel, Michael Ho, 2004, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Phase I study of fotemustine in pediatric patients with refractory brain tumors

S. Baruchel, D. Hargrave, E. Bouffet, 2002, Cancer.

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.

David T. W. Jones, R. Weksberg, N. Alon, 2013, The Lancet. Oncology.

Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors

S. Baruchel, U. Bartels, Bing Wu, 2014, Pediatric blood & cancer.

Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.

S. Baruchel, H. Yeger, Sushil Kumar, 2013, Translational oncology.

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

S. Baruchel, R. Kerbel, S. Man, 2011, Clinical Cancer Research.

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.

S. Baruchel, H. Yeger, D. Kaplan, 2009, Neoplasia.

Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood.

S. Baruchel, R. Kerbel, L. Becker, 2003, Medical and pediatric oncology.

Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction

G. Koren, S. Baruchel, D. Malkin, 2008, Stem cells.

Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling.

S. Baruchel, M. Mansukhani, Jianzhong Huang, 2006, Cancer research.

The Role of Angiogenesis in the Transformation of Plexiform Neurofibroma into Malignant Peripheral Nerve Sheath Tumors in Children With Neurofibromatosis Type 1

S. Baruchel, Charles Smith, M. Greenberg, 2010, Journal of pediatric hematology/oncology.

Metronomic Chemotherapy in Pediatric Malignancies

S. Baruchel, Sushil Kumar, R. Mokhtari, 2014 .

Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK?

S. Baruchel, S. Bowdin, M. Meyn, 2014, Journal of pediatric hematology/oncology.

Drug combinations: A strategy to enhance anti-tumor activity and overcome drug resistance to ALK inhibitors in neuroblastoma

S. Baruchel, Libo Zhang, 2021, Therapeutic Strategies to Overcome ALK Resistance in Cancer.

Advances in ALK Targeted Therapy for Neuroblastoma

S. Baruchel, Libo Zhang, 2017 .

Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12–q21

Nazneen Rahman, Michael R. Stratton, Jerry Pelletier, 1996, Nature Genetics.

Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children

G. Koren, S. Baruchel, A. Freeman, 2001, European journal of haematology.

The Idea and Evidence for the Tumor Stemness Switch

S. Baruchel, D. Malkin, H. Yeger, 2009 .

Massive intrathoracic tumor in a relatively asymptomatic boy.

S. Baruchel, G. Taylor, S. Morris, 2007, Pediatric annals.

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Peter Bohlen, Robert S. Kerbel, S. Baruchel, 2000 .

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

S. Baruchel, D. Hicklin, P. Bohlen, 2000, The Journal of clinical investigation.

Maternal malignancy involving the products of conception: a report of malignant melanoma and medulloblastoma.

S. Baruchel, L. Kovács, M. Bernstein, 1994, The American journal of pediatric hematology/oncology.

The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium.

D. Johnston, D. Eisenstat, S. Baruchel, 2011, Current oncology.

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

E. Eisenhauer, S. Baruchel, M. Bernstein, 2013, Pediatric blood & cancer.

A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.

C. Portwine, C. Hawkins, S. Baruchel, 2009, European journal of cancer.

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

S. Baruchel, P. Adamson, F. Balis, 2012, Clinical Cancer Research.

Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial.

S. Baruchel, P. Adamson, F. Balis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pseudomembranous colitis in sickle cell disease responding to exchange transfusion.

S. Baruchel, D. Sigalet, A. Hong, 1992, The Journal of pediatrics.

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

S. Baruchel, C. Ahern, P. Adamson, 2012, Cancer Chemotherapy and Pharmacology.

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

S. Baruchel, C. Ahern, P. Adamson, 2011, Clinical Cancer Research.

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

S. Baruchel, L. Seymour, D. Tu, 2018, Pediatric blood & cancer.

Relief of sickle cell priapism by hydralazine. Report of a case.

S. Baruchel, M. Bernstein, J. Rees, 1993, The American journal of pediatric hematology/oncology.

A strategy for controlling potential interactions between natural health products and chemotherapy: a review in pediatric oncology.

S. Baruchel, D. Seely, D. Stempak, 2007, Journal of pediatric hematology/oncology.

MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature.

M. Shago, S. Baruchel, K. Langenberg-Ververgaert, 2019, Journal of pediatric hematology/oncology.

Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors

S. Baruchel, P. Thorner, Libo Zhang, 2013, Clinical Cancer Research.

Using puppetry to elicit children's talk for research.

I. Epstein, B. Stevens, P. Mckeever, 2008, Nursing inquiry.

Modulation of Celecoxib Pharmacokinetics by Food in Pediatric Patients

G. Koren, S. Baruchel, J. Halton, 2005, Clinical pharmacology and therapeutics.

Successful liver transplantation in an infant with stage 4S(M) neuroblastoma

S. Baruchel, V. Ng, B. Kamath, 2013, Pediatric blood & cancer.

S. Baruchel, M. Barrera, N. D'agostino, 2005, Palliative and Supportive Care.

A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.

Herman Yeger, David Malkin, M. Shibuya, 2005, Cancer research.

Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma

S. Baruchel, D. Kaplan, L. Hansford, 2007, Oncogene.

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

S. Baruchel, M. Yalon, Jeffrey C. Allen, 2014, Neuro-oncology.

Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.

S. Baruchel, C. Ahern, J. Reid, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kasabach–Merritt phenomenon: a single centre experience

S. Mahant, S. Baruchel, V. Blanchette, 2010, European journal of haematology.

A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors

G. Koren, S. Baruchel, A. Moghrabi, 2006, Journal of pediatric hematology/oncology.

Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.

N. André, E. Pasquier, S. Baruchel, 2011, Translational oncology.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

S. Baruchel, B. Yeh, R. Kelley, 2013, British Journal of Cancer.

A pilot study of low‐dose anti‐angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893

S. Baruchel, D. Malkin, M. Bernstein, 2013, Pediatric blood & cancer.

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.

S. Baruchel, M. Coppes, D. Hargrave, 2006, European journal of cancer.

Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas

Mark L. Greenberg, S. Baruchel, M. Fouladi, 1998, Child's Nervous System.

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study

C. Ross, B. Carleton, S. Baruchel, 2017, Canadian journal of kidney health and disease.

Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology

S. Baruchel, D. Seely, D. Stempak, 2006, Cancer investigation.

Metastatic neuroblastoma presenting as a mandibular mass.

S. Baruchel, R. Cotton, E. Azouz, 1992, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling

M. Shibuya, G. Koren, S. Baruchel, 2008, Oncogene.

Celecoxib in Human Milk: A Case Report

G. Koren, S. Baruchel, D. Knoppert, 2003, Pharmacotherapy.

Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens

J. Moffat, M. Marra, O. Morozova, 2010, EMBO molecular medicine.

A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

S. Baruchel, A. Chen, C. Ahern, 2012, Clinical Cancer Research.

Phase I trial of a twice‐daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma

Mark L. Greenberg, G. Koren, S. Baruchel, 2001, Cancer.

Cytochrome P450 2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient

G. Koren, S. Baruchel, M. Linder, 2005, Clinical pharmacology and therapeutics.

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

S. Baruchel, P. Adamson, A. Pappo, 2012, European journal of cancer.

Associations Between Dietary Antioxidant Intake and Oxidative Stress in HIV‐Seropositive and HIV‐Seronegative Men and Women

S. Baruchel, S. Kubow, R. Lalonde, 2002, Journal of acquired immune deficiency syndromes.

Parental decision making in pediatric cancer end-of-life care: using focus group methodology as a prephase to seek participant design input.

P. Hinds, S. Baruchel, H. Llewellyn-Thomas, 2006, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Single‐dose and steady‐state pharmacokinetics of celecoxib in children

G. Koren, S. Baruchel, J. Gammon, 2002, Clinical pharmacology and therapeutics.

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.

S. Baruchel, H. Ahmadzadehfar, R. Vali, 2017, Current Radiopharmaceuticals.

Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.

S. Baruchel, D. Cervi, Y. Ben-David, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models

S. Baruchel, M. Ganguly, R. Vali, 2017, Contrast media & molecular imaging.

Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial.

S. Baruchel, C. Ahern, P. Adamson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide.

S. Baruchel, R. Kerbel, Y. Shaked, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

S. Baruchel, B. Geoerger, G. Vassal, 2018, European journal of cancer.

Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).

S. Baruchel, B. Geoerger, G. Vassal, 2016 .